KKKyu Ri Kang

Kyu Ri Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kyu Ri Kang has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Seroprevalence of Immunoglobulin G Antibodies to Pertussis Toxin Measured by in House Enzyme-Linked Immunosorbent Assay in Korean Children and Adults

    by Woosuck Suh, Kyu-Ri Kang, Hyun Mi Kang, Ui Yoon Choi, Eun Lee, Hyun-Woo Choi, Dongsub Kim, Ji Yeon Ham, Hyunhye Kang, Dong Hyun Kim, et al.

    Suh W, et al. J Korean Med Sci. 2027 Mar;42:e46. https://doi.org/10.3346/jkms.2027.42.e46

  • Open Access

    Emergence of Macrolide-Resistant Bordetella pertussis Harboring the A2047G Mutation During the 2024 Pertussis Outbreak in Korea

    by YeJi Kim, Kyu Ri Kang, Yi Hyeon Kwon, Yoon Kyung Cho, Bin Ahn, Seung Ha Song, Byung Ok Kwak, Dong Hyun Kim, Jin Lee, Soo Young Lee, et al.

    Kim Y, et al. J Korean Med Sci. 2026 Dec;41:e307. https://doi.org/10.3346/jkms.2026.41.e307

  • Open Access

    Assessing the Age-Specific Seroepidemiology of Varicella-Zoster Virus in Korea in the Post-COVID-19 Era Using an Acetone-Fixed Cell FAMA Assay

    by Kyu-Ri Kang, Gyu-Won Cho, Hye-Sook Jeong, June-Woo Lee, Ah-Ra Kim, Hyunhye Kang, Dongsub Kim, Dong Ho Kim, Dong Hyun Kim, Jimyung Kim, et al.

    Kang KR, et al. J Korean Med Sci. 2026 Nov;41:e271. https://doi.org/10.3346/jkms.2026.41.e271

  • Open Access

    Comparison of ELISA Versus FAMA Titers in Children After Chemotherapy and Hematopoietic Stem Cell Transplantation Who Received the Live Attenuated MAV/06 Strain Varicella Vaccine

    by Bin Ahn, Kyu Ri Kang, Ye Ji Kim, Yoon Kyung Cho, Suejung Jo, Jae Won Yoo, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Dae Chul Jeong, et al.

    Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy. Additionally, it sought to compare fluorescent-antibody-to-membrane-antigen (FAMA) and enzyme-linked immunosorbent assay (ELISA) titers to establish effective cut-off levels for protection against varicella. Methods: The FAMA assay was conducted at the Vaccine Bio Research Institute, and a VARICELLA-ZOSTER ELISA (Vircell, Granada, Spain) kit, which relies on lysate from whole cells infected with VZV, was used to determine VZV IgG. A prospective cohort study was conducted with 76 pediatric patients under 18 years old who tested negative for VZV IgG via ELISA. Patients post-HSCT and post-chemotherapy were included. Participants received the MAV/06 varicella vaccine, and serologic responses were evaluated using ELISA and FAMA. Results: The median age of participants was 9.8 years, with acute lymphoid leukemia and acute myeloid leukemia being the most common underlying disease. Post-dose 1, the seropositive rate was 56.1% by ELISA and 97.2% by FAMA. Based on the FAMA seropositive cut-off ≥1:4, post-dose 1 geometric mean titers (GMTs) of seropositive patients in the post-HSCT group were 14.7 (95% CI, 11.3–19.1) versus 20.2 (95% CI, 13.0–31.3) in the post-chemotherapy group (p = 0.690). Based on a FAMA seropositive cut-off ≥1:16, the post-dose 1 GMT of patients considered seropositive in the post-HSCT group was 19.3 (95% CI, 15.6–24.0) versus 34.1 (95% CI, 21.0–55.4) in the post-chemotherapy group (p = 0.116), and post-dose 2 FAMA titers of 76.1 (95% CI, 14.6–398.1) in the post-HSCT group and 64.0 (95% CI, 11.4–358.1) in the post-HSCT group (p = 0.853) were observed. In patients with lower baseline FAMA titers (1:4 to 1:8), 66.7% in the post-HSCT group and 71.5% in the post-chemotherapy group achieved a greater than four-fold increase in FAMA titers post-dose 1, while those with higher baseline titers (≥1:16) did not. There were no serious adverse events or vaccine-related rashes occurring in any of the patients. Conclusion: The MAV/06 varicella vaccine is immunogenic in pediatric patients post-HSCT and post-chemotherapy, particularly when administered in a two-dose schedule using a cut-off FAMA titer of <1:16.


  • Open Access

    Immunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls

    by Mi Yeon Hur, Kyu Ri Kang, Ye Ji Kim, Yoon Kyung Cho, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Dae Chul Jeong, Jin Han Kang, Hyun Mi Kang

    Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody persistence of the 2021–2022 seasonal quadrivalent influenza vaccine in pediatric patients post-HSCT or chemotherapy, compared to healthy controls. A prospective cohort study included 80 pediatric participants divided into three groups: chemotherapy (n = 33), HSCT (n = 27), and healthy controls (n = 20). All participants were vaccinated with the 2021–2022 GC FLU Quadrivalent vaccine. Hemagglutination inhibition (HI) assays measured seroprotection rates (SPR), geometric mean titers (GMT), and seroconversion rates (SCR) for the four vaccine antigens (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) at one, three, and six months post-vaccination. At one month post-vaccination, all groups met the 70% SPR threshold for A/H1N1 and A/H3N2, but not for B/Victoria. For B/Yamagata, the SPR was low in the chemotherapy and HSCT groups (18.18% and 33.33%, respectively), compared to 80.00% in controls (p < 0.0001 and p = 0.0015). While A/H1N1 and A/H3N2 GMTs were protective in all groups, only controls achieved protective levels for B/Yamagata. Over time, the control group maintained >70% SPR for A/H1N1 up to six months, but the chemotherapy and HSCT groups declined by three and six months, respectively. For A/H3N2, the SPR in controls dropped below 70% at three months, while it remained above 70% in the chemotherapy and HSCT groups until three months. None of the groups achieved protective GMTs for B strains at three or six months. Pediatric patients post-HSCT or chemotherapy demonstrated a comparable immune response to healthy controls for A/H1N1 and A/H3N2, but the rapid decline in A/H1N1 antibody levels suggests the need for ongoing monitoring and adjusted vaccination schedules. The poor response to B antigens, particularly B/Yamagata, underscores the need for improved vaccination strategies in these vulnerable populations.


  • Open Access

    Comparative Evaluation of Recombinant and Acellular Pertussis Vaccines in a Murine Model

    by Kyu-Ri Kang, Ji-Ahn Kim, Gyu-Won Cho, Han-Ul Kang, Hyun-Mi Kang, Jin-Han Kang, Baik-Lin Seong, Soo-Young Lee

    Since the 2000s, sporadic outbreaks of whooping cough have been reported in advanced countries, where the acellular pertussis vaccination rate is relatively high, and in developing countries. Small-scale whooping cough has also continued in many countries, due in part to the waning of immune protection after childhood vaccination, necessitating the development of an improved pertussis vaccine and vaccination program. Currently, two different production platforms are being actively pursued in Korea; one is based on the aP (acellular pertussis) vaccine purified from B. pertussis containing pertussis toxoid (PT), filamentous hemagglutin (FHA) and pertactin (PRN), and the other is based on the recombinant aP (raP), containing genetically detoxified pertussis toxin ADP-ribosyltransferase subunit 1 (PtxS1), FHA, and PRN domain, expressed and purified from recombinant E. coli. aP components were further combined with diphtheria and tetanus vaccine components as a prototype DTaP vaccine by GC Pharma (GC DTaP vaccine). We evaluated and compared the immunogenicity and the protective efficacy of aP and raP vaccines in an experimental murine challenge model: humoral immunity in serum, IgA secretion in nasal lavage, bacterial clearance after challenge, PTx (pertussis toxin) CHO cell neutralization titer, cytokine secretion in spleen single cell, and tissue resident memory CD4+ T cell (CD4+ TRM cell) in lung tissues. In humoral immunogenicity, GC DTaP vaccines showed high titers for PT and PRN and showed similar patterns in nasal lavage and IL-5 cytokine secretions. The GC DTaP vaccine and the control vaccine showed equivalent results in bacterial clearance after challenge, PTx CHO cell neutralization assay, and CD4+ TRM cell. In contrast, the recombinant raP vaccine exhibited strong antibody responses for FHA and PRN, albeit with low antibody level of PT and low titer in PTx CHO neutralization assay, as compared to control and GC DTaP vaccines. The raP vaccine provided a sterile lung bacterial clearance comparable to a commercial control vaccine after the experimental challenge in murine model. Moreover, raP exhibited a strong cytokine response and CD4+ TRM cell in lung tissue, comparable or superior to the experimental and commercial DTaP vaccinated groups. Contingent on improving the biophysical stability and humoral response to PT, the raP vaccine warrants further development as an effective alternative to aP vaccines for the control of a pertussis outbreak.


  • Open Access

    Protective effects of immunization with a novel 4 recombinant pore-forming toxoid combination vaccine in a rabbit model of systemic methicillin-resistant Staphylococcus aureus infection

    by Thomas Söderhäll, Seung-Bum Kim, Gi-Sub Choi, Kyu-Ri Kang, Joon-Hwan Ji, Bok Luel Lee, Jin-Han Kang

    Söderhäll T, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):338-347. https://doi.org/10.7774/cevr.2024.13.4.338


  • Open Access

    Development and validation of enzyme-linked immunosorbent assay for anti-mouse pertussis immunoglobulin G using international reference anti-Bordetella pertussis mouse serum NIBSC 97/642

    by Kyu-Ri Kang, Yi-Hyeon Kwon, Gyu-Won Cho, Gi-Sub Choi, Joon-Hwan Ji, Hyun-Mi Kang, Soo-Young Lee, Jin-Han Kang

    Kang KR, et al. Clin Exp Vaccine Res. 2024 Jul;13(3):242-252. https://doi.org/10.7774/cevr.2024.13.3.242

  • Open Access

    Safety assessments of recombinant DTaP vaccines developed in South Korea

    by Gi-Sub Choi, Kyu-Ri Kang, Seung-Bum Kim, Joon-Hwan Ji, Gyu-Won Cho, Hyun-Mi Kang, Jin-Han Kang

    Choi GS, et al. Clin Exp Vaccine Res. 2024 Apr;13(2):155-165. https://doi.org/10.7774/cevr.2024.13.2.155


  • A booster administration of the OKA/SK strain causes fatal disseminated varicella in an immunocompetent child

    by Hyun Mi Kang, Kyu Ri Kang, Ye Ji Kim, Jin Han Kang, Soo‐Young Lee

    Live varicella vaccines are known to provide robust immunity against varicella zoster virus (VZV) infections. However, problems with viral attenuation have led to pathogenic VZV vaccine strains causing varicella‐like rash and herpes zoster in immunocompetent children after immunization. We report the first fatal case of VZV infection caused by OKA/SK strain contained in the vaccine administrated as a booster shot in an immunocompetent child, which has been independently developed from any currently available varicella vaccines that are OKA strain or MAV/06 strain based. The patient died due to sudden pulmonary alveolar hemorrhage as a secondary complication of VZV pneumonitis. Sequencing of the four SNPs unique to the OKA/SK strain (SNP loci 14 035T; 32 626C; 58 777G; 70 319G) enabled discrimination of the strain responsible for the disseminated infection. OKA/SK strain does not have any SNPs in ORF62 postulated to be responsible for the attenuation of varicella vaccines which have been safely and effectively used world‐wide or locally, and exclusively enriches a virulent factor in ORF31 identified in parental OKA strain, thus possibly resulting in disseminated VZV infection leading to mortality. Therefore, actions need to be taken to prevent vaccine related morbidity and mortality in children.